N/A
Completed N=6,000
Targeted Adherence Intervention to Reach Glycemic Control With Insulin Therapy for Patients With Diabetes
Source: ClinicalTrials.gov NCT02846779 ↗Enrolled (actual)
6,000
Serious AEs
—
Results posted
Aug 2019
Primary outcomePrimary: Insulin Persistence — 5.4; 4.7; 4.9 Percentage of participants
Summary
The purpose of this study is to evaluate three pharmacist-outreach strategies for improving adherence to insulin among individuals with diabetes. The three approaches are equivalently-priced but vary by degree of targeting and intervention intensity.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Insulin Persistence |
5.4; 4.7; 4.9 | — |
| SECONDARY Change in Glycated Hemoglobin Level (HbA1c) |
-0.06; -0.21; -0.31 | — |
| SECONDARY Health Care Spending |
22616; 23284; 22545 | — |
| SECONDARY Number of Physician Office Visits |
7.66; 7.62; 7.50 | — |
| SECONDARY Number of Emergency Room Visits |
0.31; 0.43; 0.30 | — |
| SECONDARY Number of Hospitalizations |
0.19; 0.23; 0.21 | — |
Eligibility Criteria
Inclusion Criteria
- Commercially-insured individuals receiving medical and pharmacy health insurance benefits from Horizon Blue Cross Blue Shield of New Jersey
- At least 3 months of continuous enrollment prior to randomization
- At least 1 prescription for basal insulin, 6 months prior to randomization
- Type 2 diabetes diagnosis
Exclusion Criteria
- Patients with Medicaid or Medicare as primary insurance
Data sourced from ClinicalTrials.gov (NCT02846779). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.